# Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors

> **NCT06963281** · PHASE1 · RECRUITING · sponsor: **Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.** · enrollment: 285 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** IBI3020

## Key facts

- **NCT ID:** NCT06963281
- **Lead sponsor:** Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-29
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-03-31
- **Target enrollment:** 285 (ESTIMATED)
- **Last updated:** 2025-06-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06963281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06963281, "Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06963281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*